Heparanase is expressed in osteoblastic cells and stimulates bone formation and bone mass

Journal of Cellular Physiology

Volumn 207, Issue 3, 2006, Pages 784-792

  Kram, Vardit ^a   Zcharia, Eyal ^b   Yacoby Zeevi, Oron ^c   Metzger, Shula ^b   Chajek Shaul, Tova ^b   Gabet, Yankel ^a   Müller, Ralph ^d   Vlodavsky, Israel ^e   Bab, Itai ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Insight Ltd   (Israel)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARAN SULFATE; HEPARANASE; MESSENGER RNA; PROTEOGLYCAN; PROTEOHEPARAN SULFATE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MASS; CALVARIA; CANCER; CELL DIFFERENTIATION; CELL FUNCTION; CELL STRAIN 3T3; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HPA GENE; INFLAMMATION; MACROMOLECULE; MALE; METASTASIS; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TRABECULAR BONE; VASCULARIZATION; WOUND HEALING;

ANIMALS; BONE DENSITY; BONE MARROW; CELL PROLIFERATION; CELLS, CULTURED; FEMUR; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GLUCURONIDASE; HEPARITIN SULFATE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOGENESIS; PHENOTYPE; STROMAL CELLS;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 33646342005     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20625     Document Type: Article

References (63)

1. Alexander JM, Bab I, Fish S, Müller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M, Gazit D, Rosenblatt M. 2001. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res 16:1665-1673.
2. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y. 1999. Perlecan is essential for cartilage and cephalic development. Nat Genet 23: 354-358.
3. Bab I, Ashton BA, Gazit D, Marx G, Williamson MC, Owen ME. 1986. Kinetics and differentiation of marrow stromal cells in diffusion chambers in vivo. J Cell Sci 84:139-151.
4. Bab I, Gazit D, Chorev M, Muhlrad A, Shteyer A, Greenberg Z, Namdar M, Kahn A. 1992. Histone H4-related osteogenic growth peptide (OGP): A novel circulating stimulator of osteoblastic activity. EMBO J 11:1867-1873.
5. Bar-Ner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fuks Z, Vlodavsky I. 1987. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 70:551-557.
6. Bernfield M, Gotte M, Park P, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729-777.
7. Bhandari M, Hirsh J, Weitz JI, Young E, Venner TJ, Shaughnessy SG. 1998. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 80:413-417.
8. Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM, Kronenberg HM, Baron R, Schipani E. 2001. Activated parathyroid hormone/ parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 107:277-286.
9. David G, Bernfield M. 1998. The emerging roles of cell surface heparan sulfate proteoglycans. Matrix Biol 17:461-463.
10. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, Vlodavsky I. 2001. Heparanase as mediator of angiogenesis: Mode of action. FASEB J 15:1661-1663.
11. Erlebacher A, Derynck R. 1996. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 132:195-210.
12. Esko JD, Lindahl U. 2001. Molecular diversity of heparan sulfate. J Clin Invest 108:169-173.
13. Fairbanks MB, Mildner AM, Leone JW, Cavey GS, Mathews WR, Drong RF, Slightom JL, Bienkowski MJ, Smith CW, Bannow CA, Heinrikson RL. 1999. Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J Biol Chem 274:29587-29590.
14. Frenkel B, Capparelli C, Van Auken M, Baran D, Bryan J, Stein JL, Stein GS, Lian JB. 1997. Activity of the osteocalcin promoter in skeletal sites of transgenic mice and during osteoblast differentiation in bone marrow-derived stromal cell cultures: Effects of age and sex. Endocrinology 138:2109-2116.
15. Gallagher JT. 2001. Heparan sulfate: Growth control with a restricted sequence menu. J Clin Invest 108:357-361.
16. Gingis-Velitski S, Zetser A, Flugelman M, Vlodavsky I, Ilan N. 2004. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 279:23536-23541.
17. Goldshmidt O, Nadav L, Aingorn H, Irit C, Feinstein N, Ilan N, Zamir E, Geiger B, Vlodavsky I, Katz BZ. 2002. Human heparanase is localized within lysosomes in a stable form. Exp Cell Res 281:50-62.
18. Goldshmidt O, Zchari E, Cohen M, Aingorn H, Cohen I, Nadav L, Katz BZ, Geiger B, Vlodavsky I. 2003. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 17:1015-1025.
19. Gong F, Jemth P, Escobar Galvis ML, Vlodavsky I, Horner A, Lindahl U, Li JP. 2003. Processing of macromolecular heparin by heparanase. J Biol Chem 278: 35152-35158.
20. Grzesik WJ, Frazier CR, Shapiro JR, Sponseller PD, Robey PG, Fedarko NS. 2002. Age-related changes in human bone proteoglycan structure. Impact of osteogenesis imperfecta. J Biol Chem 277:43638-43647.
21. Harper J, Kalgsburn M. 1999. Cartilage to bone: Angiogenesis leads the way. Nat Med 5:617-618.
22. Hildebrand T, Laib A, Müller R, Dequeker J, Rüegsegger P. 1999. Direct three-dimensional morphometric analysis of human cancellous bone: Microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 14:1167-1174.
23. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. 1999. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 5:803-809.
24. Iozzo RV. 1998. Matrix proteoglycans: From molecular design to cellular function. Annu Rev Biochem 67:609-652.
25. Iozzo RV, San Antonio JD. 2001. Heparan sulfate proteoglycans: Heavy hitters in the angiogenesis arena. J Clin Invest 108:349-355.
26. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA II, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L. 2002. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303-314.
27. Kjellen L, Lindahl U. 1991. Proteoglycans: Structures and interactions. Annu Rev Biochem 60:443-475.
28. Kobayashi T, Soegiarto DW, Yang Y, Lanske B, Schipani E, McMahon AP, Kronenberg HM. 2005. Indian hedgehog stimulates periarticular chondrocyte differentiation to regulate growth plate length independently of PTHrP. J Clin Invest 115:1734-1742.
29. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764.
30. Kussie PH, Hulmes JD, Ludwig DL, Patel S, Navarro EC, Seddon AP, Giorgio NA, Bohlen P. 1999. Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun 261:183-187.
31. Levy-Adam F, Miao HQ, Heinrikson RL, Vlodavsky I, Ilan N. 2003. Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophys Res Commun 308:885-891.
32. Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ, Stein JL, Stein GS. 2004. Regulatory controls for osteoblast growth and differentiation: Role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 14:1-41.
33. Manolagas SC. 2000. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137.
34. Mansukhani A, Bellosta P, Sahni M, Basilico C. 2000. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol 149:1297-1308.
35. McKenzie E, Young K, Hircock M, Bennett J, Bhaman M, Felix R, Turner P, Stamps A, McMillan D, Saville G, Ng S, Mason S, Snell D, Schofield D, Gong H, Townsend R, Gallagher J, Page M, Parekh R, Stubberfield C. 2003. Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 373:423-435.
36. Muir JM, Hirsh J, Weitz JI, Andrew M, Young E, Shaughnessy SG. 1997. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 89:3236-3242.
37. Müller R, Rüegsegger P. 1997. Micro-tomographic imaging for the nondestructive evaluation of trabecular bone architecture. Stud Health Technol Inform 40:61-79.
38. Newman P, Bonello F, Wierzbicki AS, Lumb P, Savidge GF, Shearer MJ. 2002. The uptake of lipoprotein-borne phylloquinone (vitamin K1) by osteoblasts and osteoblast-like cells: Role of heparan sulfate proteoglycans and apolipoprotein E. J Bone Miner Res 17:426-433.
39. Okada Y, Yamada S, Toyoshima M, Dong J, Nakajima M, Sugahara K. 2002. Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J Biol Chem 277: 42488-42495.
40. Paine-Saunders S, Viviano BL, Economides AN, Saunders S. 2002. Heparan sulfate proteoglycans retain Noggin at the cell surface: A potential mechanism for shaping bone morphogenetic protein gradients. J Biol Chem 277:2089-2096.
41. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. 1987. Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
42. Parish CR, Freeman C, Hulett MD. 2001. Heparanase: A key enzyme involved in cell invasion. Biochim Biophys Acta 1471:M99-M108.
43. Pikas DS, Li JP, Vlodavsky I, Lindahl U. 1998. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 273:18770-18777.
44. Rodan GA, Noda M. 1991. Gene expression in osteoblastic cells. Crit Rev Eukaryot Gene Expr 1:85-98.
45. Roodman GD. 1999. Cell biology of the osteoclast. Exp Hematol 27:1229-1241.
46. Saijo M, Kitazawa R, Nakajima M, Kurosaka M, Maeda S, Kitazawa S. 2003. Heparanase mRNA expression during fracture repair in mice. Histochem Cell Biol 120:493-503.
47. Sasaki N, Higashi N, Taka T, Nakajima M, Irimura T. 2004. Cell surface localization of heparanase on macrophages regulates degradation of extracellular matrix heparan sulfate. J Immunol 172:3830-3835.
48. Savion N, Disatnik MH, Nevo Z. 1987. Murine macrophage heparanase: Inhibition and comparison with metastatic tumor cells. J Cell Physiol 130: 77-84.
49. Solomon L. 1964. Hereditary multiple exostosis. Am J Hum Genet 16:351-363.
50. Stampa B, Kuhn B, Liess C, Heller M, Gluer CC. 2002. Characterization of the integrity of three-dimensional trabecular bone microstructure by connectivity and shape analysis using high-resolution magnetic resonance imaging in vivo. Top Magn Reson Imaging 13:357-363.
51. Stein GS, Lian JB, Owen TA. 1990. Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J 4: 3111-3123.
52. Street J, Bao M, deGuzman L, Bunting S, Peale FV, Jr., Ferrara N, Steinmetz H, Hoeffel J, Cleland JL, Daugherty A, van Bruggen N, Redmond HP, Carano RA, Filvaroff EH. 2002. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 99: 9656-9661.
53. Sudo H, Kodama HA, Amagai Y, Yamamoto S, Kasai S. 1983. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 96:191-198.
54. Toyoshima M, Nakajima M. 1999. Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem 274:24153-24160.
55. Vlodavsky I, Friedmann Y. 2001. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108:341-347.
56. Vlodavsky I, Bar-Shavit R, Kormer G, Fuks Z. 1993. Extracellular matrix-bound growth factors, enzymes and plasma proteins. In: Rohrbach DH, Timpl R, editors. Basement membranes: Cellular and molecular aspects. Orlando, Florida: Academic Press, pp 327-343.
57. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I. 1999. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat Med 5:793-802.
58. Wight TN, Kinsella MG, Qwarnstrom EE. 1992. The role of proteoglycans in cell adhesion, migration and proliferation. Curr Opin Cell Biol 4:793-801.
59. Wiren KM, Zhang XW, Toombs AR, Kasparcova V, Gentile MA, Harada S, Jepsen KJ. 2004. Targeted overexpression of androgen receptor in osteoblasts: Unexpected complex bone phenotype in growing animals. Endocrinology 145:3507-3522.
60. Zcharia E, Metzger S, Chajek-Shaul T, Aingorn H, Elkin M, Friedmann Y, Weinstein T, Li JP, Lindahl U, Vlodavsky I. 2004. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 18:252-263.
61. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, Flugelman MY, Vlodavsky I, Ilan N. 2004. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 117:2249-2258.
62. Zimran A, Shilo S, Fisher D, Bab I. 1986. Histomorphometric evaluation of reversible heparin-induced osteoporosis in pregnancy. Arch Intern Med 146: 386-388.
63. Zou W, Schwartz H, Endres S, Hartmann G, Bar-Shavit Z. 2002. CpG oligonucleotides: Novel regulators of osteoclast differentiation. FASEB J 16: 274-282.